



IMMUNOTHERAPY FOR EARLY STAGE LUNG CANCER – PROGRESS AND POTENTIAL

DR. PATRICK FORDE

Associate Professor,
Bloomberg-Kimmel Institute
for Cancer Immunotherapy,
Johns Hopkins University

**THURSDAY,
SEPTEMBER 5
4PM**

**GLEN SITE,
RI AUDITORIUM
E S1.1129**



Patrick Forde is a medical oncologist who completed training in internal medicine and oncology in Ireland prior to undertaking a further fellowship at Johns Hopkins. He is currently Associate Professor and Member of the Bloomberg-Kimmel Institute for Cancer Immunotherapy and Director of the Thoracic Cancer Clinical Research Program at Johns Hopkins.

He has led development of a clinical-translational research program focused on the immuno-oncology of upper aerodigestive malignancies. Dr. Forde's research examines the role of immunotherapy for earlier stage lung cancer and his work has led to the development of several ongoing phase 3 trials.

He is principal investigator for several international phase 2 and 3 clinical trials of novel immunotherapy approaches for lung cancer and mesothelioma that are currently active in Europe, Asia and North America while also serving as principal investigator for the thoracic cancer immunobiology biospecimen repository at Johns Hopkins.

